Short Interest in Bioxytran, Inc. (OTCMKTS:BIXT) Declines By 54.5%

by · The Cerbat Gem

Bioxytran, Inc. (OTCMKTS:BIXT – Get Free Report) was the recipient of a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 38,100 shares, a decrease of 54.5% from the March 31st total of 83,800 shares. Based on an average trading volume of 469,300 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.1% of the company’s shares are sold short.

Bioxytran Trading Down 1.0 %

OTCMKTS:BIXT traded down $0.00 during trading hours on Monday, hitting $0.16. 4,924 shares of the company were exchanged, compared to its average volume of 260,853. The stock has a market capitalization of $16.24 million, a price-to-earnings ratio of -16.21 and a beta of 0.98. Bioxytran has a one year low of $0.06 and a one year high of $0.23. The company has a fifty day simple moving average of $0.14 and a 200 day simple moving average of $0.11.

Bioxytran (OTCMKTS:BIXT – Get Free Report) last posted its quarterly earnings data on Thursday, April 3rd. The company reported ($0.01) EPS for the quarter.

Bioxytran Company Profile

(Get Free Report)

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.

Further Reading